Guardant Health, Inc. (GH)
Health Care · Nasdaq
Guardant Health is a precision oncology company transforming cancer care with FDA-approved blood and tissue tests powered by AI analytics that span early detection, treatment selection, and disease monitoring.
What Guardant Health, Inc. does
Guardant Health is a precision oncology company that develops and commercializes advanced blood and tissue tests to improve cancer care across all stages of the disease—from early detection through treatment selection and monitoring for recurrence. The company's portfolio includes Guardant360 liquid and tissue biopsy tests for advanced cancer, Shield blood tests for colorectal cancer screening, and Guardant Reveal tests for detecting minimal residual disease in early-stage cancer, all powered by its Smart Platform that combines genomic, epigenomic, and RNA-based data with AI analytics.
Themes: ["precision oncology / liquid biopsy"]
Fundamentals
- Price$160.05 as of 2026-07-10 close
- Market cap$21.2B as of 2026-07-12
- 1-year return+212.0% as of 2026-07-10 close
- Net margin-40.1% as of 2026-07-12
- Gross margin+64.9% as of 2026-07-12
- ROE-246.6% as of 2026-07-12
- Debt / equity16.78 as of 2026-07-12
- Revenue growth (YoY)+39.6% as of 2026-07-12
- Revenue CAGR (3y)+29.8% SEC XBRL
- Beta1.63 as of 2026-07-12
Key risks (from latest filing)
["Regulatory and reimbursement risk: Continued dependence on FDA approval and payer coverage decisions for products including Shield and Shield MCD; changes in Medicare or commercial insurance coverage could materially impact revenue growth."]
Competitors & peers
- Invitae (NVTA)
Fundamentals: Finnhub, as of 2026-07-12. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.